Robeco Institutional Asset Management B.V. boosted its position in AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) by 175.1% during the second quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 525,989 shares of the specialty pharmaceutical company’s stock after buying an additional 334,811 shares during the period. Robeco Institutional Asset Management B.V. owned approximately 1.50% of AMAG Pharmaceuticals worth $9,679,000 as of its most recent filing with the SEC.

A number of other institutional investors have also recently made changes to their positions in AMAG. BlackRock Inc. increased its position in shares of AMAG Pharmaceuticals by 67,790.9% in the first quarter. BlackRock Inc. now owns 4,995,412 shares of the specialty pharmaceutical company’s stock worth $112,647,000 after buying an additional 4,988,054 shares during the last quarter. State Street Corp increased its position in shares of AMAG Pharmaceuticals by 75.2% in the first quarter. State Street Corp now owns 2,522,059 shares of the specialty pharmaceutical company’s stock worth $56,876,000 after buying an additional 1,082,366 shares during the last quarter. Dimensional Fund Advisors LP increased its position in shares of AMAG Pharmaceuticals by 152.4% in the first quarter. Dimensional Fund Advisors LP now owns 1,025,673 shares of the specialty pharmaceutical company’s stock worth $23,129,000 after buying an additional 619,370 shares during the last quarter. Perceptive Advisors LLC increased its position in shares of AMAG Pharmaceuticals by 2,768.3% in the first quarter. Perceptive Advisors LLC now owns 560,000 shares of the specialty pharmaceutical company’s stock worth $12,628,000 after buying an additional 540,476 shares during the last quarter. Finally, LSV Asset Management increased its position in shares of AMAG Pharmaceuticals by 34.0% in the first quarter. LSV Asset Management now owns 1,685,098 shares of the specialty pharmaceutical company’s stock worth $37,998,000 after buying an additional 427,238 shares during the last quarter.

Shares of AMAG Pharmaceuticals, Inc. (NASDAQ:AMAG) opened at 16.55 on Thursday. AMAG Pharmaceuticals, Inc. has a 52 week low of $16.00 and a 52 week high of $36.83. The firm’s market capitalization is $584.02 million. The company has a 50-day moving average of $18.67 and a 200-day moving average of $20.39.

AMAG Pharmaceuticals (NASDAQ:AMAG) last released its quarterly earnings results on Thursday, August 3rd. The specialty pharmaceutical company reported ($0.40) earnings per share for the quarter, topping the Thomson Reuters’ consensus estimate of ($0.58) by $0.18. The business had revenue of $158.39 million during the quarter, compared to analysts’ expectations of $158.83 million. AMAG Pharmaceuticals had a negative return on equity of 4.81% and a negative net margin of 7.58%. The firm’s revenue for the quarter was up 24.3% compared to the same quarter last year. During the same period last year, the firm posted $1.45 EPS. On average, equities analysts forecast that AMAG Pharmaceuticals, Inc. will post ($1.38) earnings per share for the current fiscal year.

TRADEMARK VIOLATION WARNING: “Robeco Institutional Asset Management B.V. Has $9.68 Million Stake in AMAG Pharmaceuticals, Inc. (AMAG)” was first posted by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece on another domain, it was stolen and reposted in violation of U.S. and international trademark and copyright law. The original version of this piece can be read at https://www.thecerbatgem.com/2017/08/31/robeco-institutional-asset-management-b-v-has-9-68-million-stake-in-amag-pharmaceuticals-inc-amag.html.

AMAG has been the subject of a number of research analyst reports. Zacks Investment Research upgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “buy” rating and set a $22.00 price target for the company in a report on Tuesday, July 11th. TheStreet downgraded shares of AMAG Pharmaceuticals from a “c” rating to a “d+” rating in a report on Friday, May 5th. Barclays PLC reiterated an “equal weight” rating and issued a $20.00 price target (down previously from $25.00) on shares of AMAG Pharmaceuticals in a report on Thursday, June 1st. Jefferies Group LLC reiterated a “buy” rating and issued a $34.00 price target (down previously from $40.00) on shares of AMAG Pharmaceuticals in a report on Wednesday, May 3rd. Finally, ValuEngine downgraded shares of AMAG Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Thursday, May 11th. Two research analysts have rated the stock with a sell rating, eleven have assigned a hold rating and two have assigned a buy rating to the company’s stock. The company presently has an average rating of “Hold” and an average target price of $28.09.

In other AMAG Pharmaceuticals news, SVP Julie Krop sold 4,938 shares of AMAG Pharmaceuticals stock in a transaction on Thursday, July 13th. The stock was sold at an average price of $20.00, for a total value of $98,760.00. Following the completion of the transaction, the senior vice president now directly owns 28,336 shares of the company’s stock, valued at approximately $566,720. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. 3.80% of the stock is owned by insiders.

AMAG Pharmaceuticals Company Profile

AMAG Pharmaceuticals, Inc is a pharmaceutical company. The Company’s segment is the manufacture, development and commercialization of products and services for use in treating various conditions, with a focus on maternal health, anemia management and cancer supportive care. Its offerings focus on maternal health, anemia management and cancer supportive care, including its product, Makena (hydroxyprogesterone caproate injection); services related to the collection, processing and storage of umbilical cord blood stem cell and cord tissue units operated through Cord Blood Registry (CBR); its product, Feraheme (ferumoxytol), for intravenous (IV) use, and MuGard Mucoadhesive Oral Wound Rinse.

Institutional Ownership by Quarter for AMAG Pharmaceuticals (NASDAQ:AMAG)

Receive News & Stock Ratings for AMAG Pharmaceuticals Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for AMAG Pharmaceuticals Inc. and related stocks with our FREE daily email newsletter.